A TVA-single-chain antibody fusion protein mediates specific targeting of a subgroup A avian leukosis virus vector to cells expressing a tumor-specific form of epidermal growth factor receptor

Journal of Virology

Volumn 74, Issue 20, 2000, Pages 9540-9545

  Snitkovsky, S ^a   Niederman, T M J ^a   Carter, B S ^a   Mulligan, R C ^a   Young, J A T ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR; HYBRID PROTEIN;

ARTICLE; AVIAN LEUKOSIS ONCOVIRUS; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN TARGETING; RECEPTOR BINDING; SIGNAL TRANSDUCTION; VIRUS VECTOR;

CELL LINE; GENETIC VECTORS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMAN; LEUKOSIS VIRUS, AVIAN; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VIRUS; RECOMBINANT FUSION PROTEINS; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0033813743     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.20.9540-9545.2000     Document Type: Article

References (58)

1. Retroviral display of antibody fragments; interdomain spacing strongly influences vector infectivity
2. A receptor for subgroup A Rous sarcoma virus is related to the low density lipoprotein receptor
3. Importance of cysteines in the LDLR-related domain of the subgroup A avian leukosis and sarcoma virus receptor for viral entry
4. Targeting retroviral vectors to CD34-expressing cells: Binding to CD34 does not catalyze virus-cell fusion
5. Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types
6. Genetic analysis of the Rous sarcoma virus subgroup D env gene: Mammal tropism correlates with temperature sensitivity of gp85
7. Modification of retroviral tropism by display of IGF-I
8. Retroviral vector particles displaying the antigen-binding site of an antibody enable cell-type-specific gene transfer
9. Toward highly efficient cell-type-specific gene transfer with retroviral vectors displaying single-chain antibodies
10. Cell targeting with retroviral vector particles containing antibody-envelope fusion proteins
11. Retroviral retargeting by envelopes expressing an N-terminal binding domain
12. Targeting retrovirus entry
13. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors
14. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails
15. Inverse targeting of retroviral vectors: Selective gene transfer in a mixed population of hematopoietic and nonhematopoietic cells
16. Development of a flexible and specific gene delivery system for production of murine tumor models
17. Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas
18. Targeting retroviral vectors to vascular lesions by genetic engineering of the MoMLV gp70 envelope protein
19. Ligand-directed retroviral targeting of human breast cancer cells
20. Retroviral display of functional binding domains fused to the amino terminus of influenza hemagglutinin
21. A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice
22. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling
23. Gene therapy of metastatic cancer by in vivo retroviral gene targeting
24. Cell-type-specific gene transfer into human cells with retroviral vectors that display single-chain antibodies
25. In vivo cell type-specific gene delivery with retroviral vectors that display single chain antibodies
26. A genetically engineered spleen necrosis virus-derived retroviral vector that displays the HIV type 1 glycoprotein 120 envelope peptide
27. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions
28. Targeting strategy for gene delivery to carcinoembryonic antigen-producing cancer cells by retrovirus displaying a single-chain variable fragment antibody
29. Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: Targeting with a single chain antibody variable domain isolated by phage display
30. Selective amplification of the cytoplasmic domain of the epidermal growth factor receptor gene in glioblastoma multiforme
31. Targeted infection of human ceils via major histocompatibiilty complex class I molecules by Moloney murine leukemia virus-derived viruses displaying single-chain antibody fragment-envelope fusion proteins
32. Retroviral vector targeting to melanoma cells by single-chain antibody incorporation in envelope
33. Retrovirus targeting by tropism restriction to melanoma cells
34. Targeted infection of a retrovirus bearing a CD4-Env chimera into human cells expressing human immunodeficiency virus type 1
35. Efficient gene delivery to quiescent interleukin-2 (IL-2)-dependent cells by murine leukemia virus-derived vectors harboring IL-2 chimeric envelope glycoproteins
36. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection
37. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors
38. Amphotropic retroviral vectors displaying hepatocyte growth factor-envelope fusion proteins improve transduction efficiency of primary hepatocytes
39. Targeting of retroviral vectors through protease-substrate interactions
40. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity
41. A gene delivery system activatable by disease-associated matrix metalloproteinases
42. Selective transduction of protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors
43. Integration of murine leukemia virus DNA depends on mitosis
44. Retroviral vectors displaying functional antibody fragments
45. The EV-O-derived cell line DF-1 supports the efficient replication of avian leukosis-sarcoma viruses and vectors
46. Expression of chimeric envelope proteins in helper cell lines and integration into Moloney murine leukemia virus particles
47. Cell-specific viral targeting mediated by a soluble retroviral receptor-ligand fusion protein
48. Generation of targeted retroviral vectors by using single-chain variable fragment: An approach to in vivo gene delivery
49. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas
50. Differential utilization of SHCA tyrosine residues and functional domains in the transduction of epidermal growth factor-induced mitigen-activated protein kinase activation in 293T cells and nerve growth factor-induced neurite outgrowth in PC12 cells - Identification of a new GRB2-center-DOT-SOS1 binding site
51. Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors
52. Receptor co-operation in retrovirus entry: Recruitment of an auxiliary entry mechanism after retargeted binding
53. Improvement of retroviral retargeting by using amino acid spacers between an additional binding domain and the N terminus of Moloney murine leukemia virus SU
54. Gene therapypromises, problems and prospects
55. Structural alterations of the epidermal growth factor receptor gene in human gliomas
56. Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c-erbB) in human brain tumors
57. Identification of the block in targeted retroviral-mediated gene transfer
58. Residue Trp-48 of Tva is critical for viral entry but not for high-affinity binding to the SU glycoprotein of subgroup A avian leukosis and sarcoma viruses